Specifications
- HOST SPECIES: Mouse
- SPECIES REACTIVITY: Human
- IMMUNOGEN: LIGHT antibody was raised against the extracellular domain of human LIGHT.
- CONJUGATE: Unconjugated
- TESTED APPLICATIONS: E, Flow, ICC, IF, IHC-P, WB
- APPLICATION NOTE: LIGHT antibody can be used for detection of CD80 by Western blot at 0.5 - 1 μg/mL. LIGHT antibody can be used for immunohistochemistry starting at 2 - 5 μg/mL. For immunofluorescence start at 20 μg/mL.
Antibody validated: Western Blot in human samples; Immunohistochemistry in human samples; Immunocytochemistry in human samples; Immunofluorescence in human samples and Flow Cytometry in mouse samples. All other applications and species not yet tested. - POSITIVE CONTROL 1: Cat. No. 1331 - Human Lymphoma Tissue Lysate
- PREDICTED MOLECULAR WEIGHT: Predicted: 26 kDa
Properties
- PURIFICATION: LIGHT Antibody is supplied as protein A purified IgG2b.
- CLONALITY: Monoclonal
- ISOTYPE: IgG2b
- PHYSICAL STATE: Liquid
- BUFFER: LIGHT Antibody is supplied in PBS containing 0.02% sodium azide and 50% glycerol.
- CONCENTRATION: 1 mg/mL
- STORAGE CONDITIONS: LIGHT antibody can be stored at 4°C for three months and -20°C, stable for up to one year. As with all antibodies care should be taken to avoid repeated freeze thaw cycles. Antibodies should not be exposed to prolonged high temperatures.
Additional Info
- NCBI OFFICIAL SYMBOL: TNFSF14
- ADDITIONAL NAMES: LIGHT Antibody: TNFSF14, LTg, CD258, HVEML, HVEM ligand
- Protein Accession Number: NP_003798
- PROTEIN GI NUMBER: 25952144
- NCBI GENE ID NUMBER: 8740
- USER NOTE: Optimal dilutions for each application to be determined by the researcher.
Background
- LIGHT Antibody: LIGHT, also known as Tumor Necrosis Factor Superfamily member 14 (TNFSF14), is a co-stimulatory molecule that can regulate T-cell activation (1) and has recently been identified as an immune checkpoint protein. LIGHT binds to two different receptors, Herpes Virus Entry Mediator (HVEM) and Lymphotoxin beta Receptor (LTβR). While LIGHT binding to HVEM delivers a co-stimulatory signal to T cells (1), LIGHT binding to LTβR is critical for the formation of lymphoid structures which can stimulate T cell infiltration and activation of a tumor microenvironment, leading to rapid T cell-mediated tissue destruction (2). It has been shown that targeted delivery of LIGHT to tumors, thereby causing the T cell infiltration of the tumor, can enhance the response of the PD-1/PD-L1 checkpoint blockade anti-cancer therapy (3), suggesting that LIGHT may become a potent tool in anti-cancer treatment.
- 1: Wang Y, Zhu M, Miller M, et al. Immunoregulation by tumor necrosis factor superfamily member LIGHT. Immunological Reviews 2009; 229:232–43.
- 2: Lee Y, Chin RK, Christiansen P, et al. Recruitment and activation of naive T cells in the islets by lymphotoxin beta receptor-dependent tertiary lymphoid structure. Immunity 2006; 25:499-509.
- 3: Tang H, Wang Y, Chlewicki LK, et al. Facilitating T cell infiltration in tumor microenvironment overcomes resistance to PD-L1 blockade. Cancer Cell 2016; 29:285-296.
Disclaimer
- FOR RESEARCH USE ONLY
For additional information, visit ProSci's Terms & Conditions Page. - Disclaimer: Optimal dilutions/concentrations should be determined by the end user. The information provided is a guideline for product use. This product is for research use only.
Shipping Info
$65 Standard Overnight flat rate for as many products shipped within the United States.
$35 Dry Ice Shipment fee may be required on some items.
Note: Online orders only accepted for shipment within the USA. Click here for the list of international distributors.